None of the other examined polymorphisms (<i>AKT1</i> rs1130214, <i>AKT1</i> rs3730358, <i>mTOR</i> rs1883965) revealed significant association with BC.
In conclusion, our findings suggest that <i>PIK3CA</i> rs6443624, <i>AKT1</i> rs2498801, <i>AKT1</i> rs1130233, as well <i>mTOR</i> rs2295080 polymorphism may be related to bladder cancer development in a sample of Iranian population.
The <i>AKT1</i> rs2498801 variant is associated with a decreased risk of BC (OR=0.57, 95 % CI=0.39-0.82, p=0.003, AG vs AA; OR=0.74, 95 % CI=0.56-0.97, p=0.032, G vs A) while, AKT1 rs1130233 polymorphism considerably increased the risk of BC (OR=3.70, 95 % CI=2.52-5.43, p<0.0001, GA vs GG; OR=5.81, 95 % CI=1.53-21.97, p=0.010, AA vs GG; OR=2.71, 95 % CI=1.98-3.70, p<0.0001, A vs G).
None of the other examined polymorphisms (<i>AKT1</i> rs1130214, <i>AKT1</i> rs3730358, <i>mTOR</i> rs1883965) revealed significant association with BC.